John S. Link

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Concurrent Trastuzumab and HER2/<i>neu</i>-Specific Vaccination in Patients With Metastatic Breast Cancer

Mary L. Disis, Danelle R. Wallace, Theodore A. Gooley et al. · Journal of Clinical Oncology · 2009 · 296 citations · Full text

The Mechanisms and Prognostic Significance of Seminal Vesicle Involvement by Prostate Cancer

Makoto Ohori, Peter T. Scardino, STEPHEN L. LAPIN et al. · The American Journal of Surgical Pathology · 1993 · 233 citations

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Arlene Chan, Beverly Moy, Janine Mansi et al. · Clinical Breast Cancer · 2020 · 211 citations · Full text

Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients

Robert Alan Nagourney, John S. Link, Jonathan B. Blitzer et al. · Journal of Clinical Oncology · 2000 · 105 citations